Tango Therapeutics (TNGX) Return on Capital Employed (2021 - 2026)
Tango Therapeutics (TNGX) recorded quarterly Return on Capital Employed of 6.84% in Q1 2026, up 9.31% quarter-over-quarter from 7.55% in Q4 2025, and up 4937.0% on a YoY basis from 0.14% in Q1 2025.
Tango Therapeutics (TNGX) Return on Capital Employed (2021 - 2026) Analysis & Trends
Tango Therapeutics' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 6.84% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 4937.0% year-over-year to 6.84%; the TTM figure through Mar 2026 stood at 6.84% (up 4937.0% YoY), while the FY2025 annual figure was 6.35%, up 3895.0% from the prior year.
- Return on Capital Employed was 6.84% for Q1 2026 at Tango Therapeutics, up from 7.55% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 6.84% in Q1 2026 to a low of 72.79% in Q2 2025.
- Historically, Return on Capital Employed has averaged 34.1% across 5 years, with a median of 31.65% in 2023.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed sank 3495 bps in 2025, then jumped 4937 bps in 2026.
- A 5-year view of Return on Capital Employed shows it stood at 28.14% in 2022, then slipped by 10 bps to 30.9% in 2023, then tumbled by 59 bps to 49.14% in 2024, then jumped by 85 bps to 7.55% in 2025, then grew by 9 bps to 6.84% in 2026.
- The last three Return on Capital Employed figures came in at 6.84% (Q1 2026), 7.55% (Q4 2025), and 53.67% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Tango Therapeutics | 4.05 Bn | 3.67 Bn | - | -6.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.84% |
| Dec 31, 2025 | -7.55% |
| Sep 30, 2025 | -53.67% |
| Jun 30, 2025 | -72.79% |
| Mar 31, 2025 | -56.22% |
| Dec 31, 2024 | -49.14% |
| Sep 30, 2024 | -42.42% |
| Jun 30, 2024 | -37.85% |
| Mar 31, 2024 | -34.88% |
| Dec 31, 2023 | -30.90% |
| Sep 30, 2023 | -30.45% |
| Jun 30, 2023 | -33.74% |
| Mar 31, 2023 | -31.65% |
| Dec 31, 2022 | -28.14% |
| Sep 30, 2022 | -25.31% |
| Jun 30, 2022 | -22.19% |
| Mar 31, 2022 | -16.01% |
| Dec 31, 2021 | -12.26% |
| Sep 30, 2021 | -11.86% |
| Jun 30, 2021 | -26.01% |